The Shield Sign of Carcinoma Hemorrhagiectoides
Clicks: 7
ID: 322968
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.8
/100
7 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #51 of 304 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 304 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A 75-year-old man presented to dermatology clinic with a rapidly expanding violaceous plaque across the right side of his chest, crossing midline. Biopsy demonstrated poorly differentiated, angioinvasive epithelioid cells. Immunohistochemical and imaging work-up led to a diagnosis of metastatic salivary duct carcinoma. The patient was diagnosed with carcinoma hemorrhagiectoides, a distinct inflammatory pattern of intravascular cutaneous metastases. This clinical presentation is termed the Shield Sign, due to lesion distribution resembling a medieval knight’s shield1,2. The Shield Sign is rare and has only been reported in association with salivary duct and breast cancers. Its presentation should prompt a work-up for malignancy.
| Reference Key |
openalex_W7171877633
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kyle Mueller, Philip R Cohen, Drew Kuraitis |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag316
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.